Rocket Pharmaceuticals Inc 2025年度报告

(Mark One) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YesԊNoԊ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. YesԊNoշ Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filingrequirements for the past 90 days. YesշNoԊ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).YesշNoԊ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company”in Rule 12b-2 of the Exchange Act. Large accelerated filerNon-accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.Ԋ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internalcontrol over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared orissued its audit report.Ԋ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included inthe filing reflect the correction of an error to previously issued financial statements.Ԋ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensationreceived by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).Ԋ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesԊNoշ The aggregate market value of the common stock held by non-affiliates of the registrant as of June 30, 2025 (the last business day of the registrant’smost recently completed second fiscal quarter) was approximately $212.5 million, based upon the closing price on the NASDAQ Global Market reported forsuch date. As of February 20, 2026, there were 108,569,143 shares of common stock, $0.01 par value per share, outstanding. Documents Incorporated by Reference Part III of this annual report on Form 10-K incorporates by reference information (to the extent specific sections are referred to herein) from theregistrant’s definitive proxy statement for its 2026 Annual Meeting of Stockholders (the “Proxy Statement”). The Proxy Statement will be filed with theUnited States Securities and Exchange Commission within 120 days of the end of the period covered by this Annual Report on Form 10-K. Table of Contents PagePART I.Item 1.Business9Item 1A.Risk Factors37Item 1B.Unresolved SEC Comments64Item 1C.Cybersecurity64Item 2.Properties65Item 3.Legal Proceedings65Item 4.Mine Safety Disclosures66 PART II.Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities67Item 6.Reserved67Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations67Item 7A.Quantitative and Qualitative Disclosures About Market Risk76Item 8.Financial Statements and Supplementary Data76Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure76Item 9A.Controls and Procedures76Item 9B.Other Information77Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections77 Item 10.Directors, Executive Officers, and Corporate Governance78Item 11.Executive Compensation78Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters78Item 13.Certain Relationships and Related Transactions, and Director Independence78Item 14.Principal Accountant Fees and Services78 PART IVItem 15. Exhibits and Financial Statement Schedules79Item 16.Form 10-K Summary81Signatures82 Summary of Abbreviated Terms Rocket Pharmaceuticals, Inc. may be referred to as Rocket, the Company, we, our or us, in this Annual Report on Form 10-K(the “Annual Report”), unless the context otherwise indicates. Throughout this Annual Report, we have used terms which are definedbelow: This Annual Report contain